Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.
We present the video of Ed and Jeff's review of first day's science at the European HD Network meeting in Barcelona.
Ed and Jeff present the second day's science at the EHDN meeting in Barcelona. Features a clinical trials roundup, an exclusive interview with Prof Sarah Tabrizi about the first trial of a huntingtin lowering 'gene silencing' drug, and a surprise for EHDN president Prof Bernhard Landwehrmeyer.
Many people with Huntington's disease have problems sleeping. Sleep-wake cycles are controlled in part by melatonin, a hormone that makes you drowsy at bedtime. Scientists in London measured melatonin levels in HD patients, gene carriers, and unaffected individuals and found changes in the levels and timing of melatonin release. This could help to explain the sleep disruptions that occur in HD.
Our final report from the European HD Network meeting. For the first time, video of many presentations, including our 'EuroBuzz' sessions will be made available online shortly.
Here's Ed and Jeff's live Twitter report from the second day of the EHDN 2014 meeting. Our final report will be tomorrow, and we'll be uploading video of our onstage roundup sessions soon.
Join Jeff and Ed as we tweet live from the 2014 European Huntington's Disease Network meeting in Barcelona! Exciting science ahead!
We know that the cause of Huntington's disease is a genetic change, resulting a harmful protein: mutant huntingtin. But other proteins can get dragged into the fray and contribute to the problems faced by HD-affected cells. New research suggests that a rather notorious protein, called 'tau' – a known troublemaker in other degenerative brain diseases – builds up and causes damage in HD.
Cells in the brain depend on support from one another to stay alive. Nutrients called trophic factors act like brain fertilizer, keeping neighboring brain cells healthy. This process has long been thought to go wrong in HD, and exciting new mouse research paints a very clear picture of exactly what's happening.
The largest ever therapeutic trial for Huntington's disease was halted early this week because an analysis of the results to date showed that it was very unlikely to show positive results. The study, called 2CARE, was designed to test whether a treatment called coenzyme Q10 could slow the progression of HD.